ResearcherAir Force Medical UniversityNo recent work listed

Yong Zhao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5103170818. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers

Papers 3

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Changhong Shi · 2 shared papers, 2022 · strength 0.32
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
- Paper LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. DOI 10.3390/cancers14225526 ↗
He Zhang · 1 shared paper, 2022 · strength 0.16
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
Jiaze An · 1 shared paper, 2022 · strength 0.16
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
Rong Xu · 1 shared paper, 2022 · strength 0.16
- Paper LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. DOI 10.3390/cancers14225526 ↗
Yu-chun Bai · 1 shared paper, 2011 · strength 0.03
- Paper [Role of connective tissue growth factor (CTGF) in proliferation and migration of pancreatic cancer cells]. PMID 22335903 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.